Bio-Techne Corporation | Mid-cap | Healthcare
$62.95
1.39%
| Bio-Techne Stock Comparison:
Bio-Techne vs VertexBio-Techne vs RegeneronBio-Techne vs MadrigalBio-Techne vs Corcept TherapeuticsBio-Techne vs Revolution MedicinesBio-Techne vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 317.0M
Gross Profit 198.8M 62.72%
Operating Income 116.7M 36.81%
Net Income -17.7M -5.58%

Balance Sheet Metrics

Total Assets 2.6B
Total Liabilities 639.1M
Shareholders Equity 1.9B
Debt to Equity 0.33

Cash Flow Metrics

Operating Cash Flow 7.6M
Free Cash Flow 93.3M

Revenue & Profitability Trend

Bio-Techne Income Statement From 2021 to 2025

Metric20252024202320222021
Revenue i1.2B1.2B1.1B1.1B931.0M
Cost of Goods Sold i429.4M389.3M366.9M349.1M298.2M
Gross Profit i790.3M769.7M769.8M756.5M632.8M
Gross Margin % i64.8%66.4%67.7%68.4%68.0%
Operating Expenses
Research & Development i99.5M96.7M92.5M87.1M70.6M
Selling, General & Administrative i415.1M396.8M352.4M339.0M289.9M
Other Operating Expenses i-----
Total Operating Expenses i514.6M493.5M444.9M426.1M360.5M
Operating Income i242.8M242.9M291.0M295.8M242.7M
Operating Margin % i19.9%21.0%25.6%26.8%26.1%
Non-Operating Items
Interest Income i3.9M3.3M3.4M794.0K473.0K
Interest Expense i8.5M15.7M11.2M11.3M14.0M
Other Non-Operating Income-139.7M-44.8M55.5M16.1M-81.0M
Pre-tax Income i98.5M185.7M338.7M301.4M148.2M
Income Tax i25.1M17.6M53.2M38.3M8.6M
Effective Tax Rate % i25.5%9.5%15.7%12.7%5.8%
Net Income i73.4M168.1M285.4M263.1M139.6M
Net Margin % i6.0%14.5%25.1%23.8%15.0%
Key Metrics
EBITDA i357.6M351.4M401.0M399.2M331.8M
EPS (Basic) i$0.47$1.07$1.81$1.73$0.91
EPS (Diluted) i$0.46$1.05$1.76$1.66$0.87
Basic Shares Outstanding i157521000157708000157179000156876000154988000
Diluted Shares Outstanding i157521000157708000157179000156876000154988000

Income Statement Trend

Bio-Techne Balance Sheet From 2021 to 2025

Metric20252024202320222021
Assets
Current Assets
Cash & Equivalents i162.2M151.8M180.6M172.6M199.1M
Short-term Investments i01.1M23.7M74.5M32.5M
Accounts Receivable i206.9M241.4M218.5M194.5M145.4M
Inventory i189.4M179.7M171.6M141.1M116.7M
Other Current Assets37.5M33.7M27.1M22.9M16.9M
Total Current Assets i608.3M617.4M621.5M605.6M510.6M
Non-Current Assets
Property, Plant & Equipment i73.4M91.3M98.3M65.6M73.8M
Goodwill i2.3B2.5B2.3B2.2B2.3B
Intangible Assets i365.6M507.1M534.6M531.5M616.0M
Long-term Investments2.8M9.8M16.9M--
Other Non-Current Assets30.1M12.1M12.6M46.8M11.6M
Total Non-Current Assets i1.9B2.1B2.0B1.7B1.8B
Total Assets i2.6B2.7B2.6B2.3B2.3B
Liabilities
Current Liabilities
Accounts Payable i25.3M38.0M25.7M33.9M29.4M
Short-term Debt i14.1M12.9M11.2M24.4M24.1M
Current Portion of Long-term Debt-----
Other Current Liabilities1.6M2.2M1.4M1.2M3.9M
Total Current Liabilities i175.8M159.4M128.5M176.0M152.3M
Non-Current Liabilities
Long-term Debt i430.0M406.6M443.8M301.5M396.5M
Deferred Tax Liabilities i6.2M55.9M89.0M99.0M93.1M
Other Non-Current Liabilities27.1M13.2M10.9M12.2M24.5M
Total Non-Current Liabilities i463.2M475.6M543.7M417.8M539.4M
Total Liabilities i639.1M635.0M672.2M593.8M691.7M
Equity
Common Stock i1.6M1.6M1.6M1.6M390.0K
Retained Earnings i1.1B1.3B1.3B1.1B1.1B
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i1.9B2.1B2.0B1.7B1.6B
Key Metrics
Total Debt i444.1M419.5M455.0M326.0M420.6M
Working Capital i432.5M458.0M493.0M429.5M358.3M

Balance Sheet Composition

Bio-Techne Cash Flow Statement From 2021 to 2025

Metric20252024202320222021
Operating Activities
Net Income i73.4M168.1M285.4M263.1M139.6M
Depreciation & Amortization i109.9M111.7M107.2M101.1M87.7M
Stock-Based Compensation i40.8M38.0M39.2M42.2M49.0M
Working Capital Changes i10.5M-9.0M-58.9M-76.9M-3.6M
Operating Cash Flow i185.6M269.0M334.2M313.7M251.4M
Investing Activities
Capital Expenditures i-31.0M-62.9M-38.2M-44.9M-44.3M
Acquisitions i-15.0M-169.7M-83.4M0-225.9M
Investment Purchases i0-5.5M-20.5M-78.0M-39.7M
Investment Sales i1.1M28.1M108.5M26.1M66.4M
Investing Cash Flow i-42.5M-210.0M-33.6M-96.9M-243.5M
Financing Activities
Share Repurchases i-275.7M-80.0M-19.6M-161.0M-43.2M
Dividends Paid i-50.4M-50.4M-50.3M-50.2M-49.6M
Debt Issuance i104.0M225.0M619.7M90.0M-
Debt Repayment i-77.0M-256.0M-525.7M-175.5M-271.5M
Financing Cash Flow i-305.6M-183.3M612.5M-405.5M-127.6M
Free Cash Flow i256.6M236.1M216.1M280.4M307.9M
Net Change in Cash i-162.5M-124.4M913.0M-188.7M-119.7M

Cash Flow Trend

Bio-Techne Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 136.85
Forward P/E 28.74
Price to Book 5.08
Price to Sales 8.04
PEG Ratio -0.96

Profitability Ratios

Profit Margin 6.02%
Operating Margin 36.30%
Return on Equity 3.68%
Return on Assets 6.30%

Financial Health

Current Ratio 3.46
Debt to Equity 23.14
Beta 1.48

Per Share Data

EPS (TTM) $0.46
Book Value per Share $12.38
Revenue per Share $7.74

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
tech9.8B136.855.083.68%6.02%23.14
Vertex 103.4B28.686.0222.77%31.86%8.89
Regeneron 63.8B14.212.0915.34%31.37%9.04
Madrigal 9.9B-20.2314.14-36.30%-54.68%17.81
Corcept Therapeutics 9.0B75.9013.9521.70%18.67%1.04
Revolution Medicines 8.7B-13.054.68-46.61%0.00%7.12

Financial data is updated regularly. All figures are in the company's reporting currency.